Abstract
Arterial thrombosis (manifested as myocardial infarction, ischaemic stroke, or peripheral occlusive artery disease) and venous thrombosis (main clinical presentations include deep vein thrombosis and pulmonary embolism) represent major health problems that are associated with high rates of morbidity and mortality, particularly in Western societies. Several lines of evidence point to a role of novel hemostatic genetic risk factors in influencing thrombotic risk. In fact, it is becoming increasingly clear that the analysis of genetic risk factors and plasmatic factors, together with private life style and environmental factors may contribute significantly to our understanding of the genetic predisposition to vascular thrombosis. The most significant breakthrough was the confirmation of the notion that inherited hypercoagulable conditions are present in a large proportion of patients with venous thromboembolism. These include mutations in the genes encoding antithrombin, protein C, protein S, factor V, and prothrombin. Moreover, plasmatic risk indicators like hyperhomocysteinemia and elevated concentrations of factors II, VIII, IX, XI and fibrinogen have also been documented. Plasma levels of proteins of the hemostatic system also predict the onset and outcome of arterial thrombosis. Several studies examined the relationship between genetic markers of the hemostatic system (platelet receptors, endothelial receptors, anticoagulant proteins, coagulation factors and proteins of the fibrinolytic system) and arterial disease. The results from these studies are frequently conflicting and often are not concordant with plasmatic studies. Therefore, large prospective studies remain needed in order to evaluate the significance of hemostatic plasma levels and gene variations in arterial thrombotic diseases.
Keywords: Genetic Variations, Hemostatic System, Risk Factors, Arterial Thrombotic Disease, platelet, fibrinolytic system
Current Genomics
Title: Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Volume: 4 Issue: 4
Author(s): R. F. Franco, M. D. Trip and P. H. Reitsma
Affiliation:
Keywords: Genetic Variations, Hemostatic System, Risk Factors, Arterial Thrombotic Disease, platelet, fibrinolytic system
Abstract: Arterial thrombosis (manifested as myocardial infarction, ischaemic stroke, or peripheral occlusive artery disease) and venous thrombosis (main clinical presentations include deep vein thrombosis and pulmonary embolism) represent major health problems that are associated with high rates of morbidity and mortality, particularly in Western societies. Several lines of evidence point to a role of novel hemostatic genetic risk factors in influencing thrombotic risk. In fact, it is becoming increasingly clear that the analysis of genetic risk factors and plasmatic factors, together with private life style and environmental factors may contribute significantly to our understanding of the genetic predisposition to vascular thrombosis. The most significant breakthrough was the confirmation of the notion that inherited hypercoagulable conditions are present in a large proportion of patients with venous thromboembolism. These include mutations in the genes encoding antithrombin, protein C, protein S, factor V, and prothrombin. Moreover, plasmatic risk indicators like hyperhomocysteinemia and elevated concentrations of factors II, VIII, IX, XI and fibrinogen have also been documented. Plasma levels of proteins of the hemostatic system also predict the onset and outcome of arterial thrombosis. Several studies examined the relationship between genetic markers of the hemostatic system (platelet receptors, endothelial receptors, anticoagulant proteins, coagulation factors and proteins of the fibrinolytic system) and arterial disease. The results from these studies are frequently conflicting and often are not concordant with plasmatic studies. Therefore, large prospective studies remain needed in order to evaluate the significance of hemostatic plasma levels and gene variations in arterial thrombotic diseases.
Export Options
About this article
Cite this article as:
Franco F. R., Trip D. M. and Reitsma H. P., Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease, Current Genomics 2003; 4 (4) . https://dx.doi.org/10.2174/1389202033490349
DOI https://dx.doi.org/10.2174/1389202033490349 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Potent Caspase-3 Inhibitors for Treatment of Multi- Neurodegenerative Diseases Using Pharmacophore Modeling and Docking Approaches
CNS & Neurological Disorders - Drug Targets Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Decoding the Transcriptional Response to Ischemic Stroke in Obese and Non-obese Mice Brain
Current Neurovascular Research Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Role of PI3 Kinase Gamma in Excitation-Contraction Coupling and Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Protein-mediated Fatty Acid Uptake in the Heart
Current Cardiology Reviews L-Arginine Availability as a Pathological Mechanism in Essential Hypertension, Chronic Renal and Heart Failure
Vascular Disease Prevention (Discontinued) Medical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions
Current Cardiology Reviews Mitochondrial Uncoupler Proteins
Current Enzyme Inhibition Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design CYP-Mediated Clozapine Interactions: How Predictable Are They?
Current Drug Metabolism Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders